Related Experiment Video
Updated: Jun 20, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Mechanistic study on growth suppression and apoptosis induction by targeting hepatoma-derived growth factor in human
Tsun Yee Tsang1, Wan Yee Tang, Wing Pui Tsang
1Department of Biochemistry, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
Abstract:
Hepatoma-derived growth factor (HDGF) is frequently overexpressed in human cancer. The growth factor was previously demonstrated to be a survival factor as knock-down of HDGF suppresses the growth and induces apoptosis in human cancer cells through the Bad-mediated intrinsic apoptotic pathway. However, inactivation of Bad cannot completely repress the apoptosis induced upon HDGF knock-down, indicating the presence of other unidentified pathways. In the present study, HDGF knock-down was shown to trigger the Fas-mediated extrinsic apoptotic pathway in human hepatocellular carcinoma HepG2 cells through NF-kappaB signaling pathway. Increases in Fas expression and fas promoter activity were detected upon HDGF knock-down by Western blot analysis and luciferase reporter assay. Knock-down of fas inhibited HDGF knock-down effect on apoptosis induction and growth suppression as revealed by annexin V binding assay and soft agar assay. Down-regulation of IkappaBalpha was also observed upon HDGF knock-down. Overexpression of IkappaBalpha by transient transfection or inhibition of NF-kappaB by BAY11-7082 suppressed HDGF knock-down effect on fas promoter activation, Fas up-regulation, apoptosis induction and growth suppression. Furthermore, the interaction of Fas-mediated extrinsic and Bad-mediated intrinsic apoptotic pathways was demonstrated as a stronger inhibition on apoptosis induction and growth suppression upon HDGF knock-down was observed when both pathways were inactivated. The results therefore suggested that, through both intrinsic and extrinsic apoptotic pathways, HDGF may function as a survival factor and be a potential target for cancer therapy.
Insights
Hepatoma-derived growth factor (HDGF) knockdown triggers apoptosis via both intrinsic and extrinsic pathways in liver cancer cells. This dual-pathway action highlights HDGF as a potential therapeutic target for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cellular Biology
Background:
- Hepatoma-derived growth factor (HDGF) is overexpressed in human cancers and acts as a survival factor.
- HDGF knockdown induces apoptosis via the Bad-mediated intrinsic pathway, but other pathways are involved.
Purpose of the Study:
- To investigate the role of HDGF in triggering apoptosis through the extrinsic pathway.
- To elucidate the involvement of NF-kappaB signaling in HDGF-mediated apoptosis.
- To explore the interplay between intrinsic and extrinsic apoptotic pathways upon HDGF knockdown.
Main Methods:
- HDGF knockdown in HepG2 cells.
- Western blot analysis and luciferase reporter assays to assess Fas expression and promoter activity.
- Annexin V binding and soft agar assays for apoptosis and growth suppression.
- NF-kappaB pathway modulation using IkappaBalpha overexpression and BAY11-7082.
Main Results:
- HDGF knockdown activated the Fas-mediated extrinsic apoptotic pathway via NF-kappaB signaling.
- Fas expression and promoter activity increased upon HDGF knockdown.
- Inactivating Fas or NF-kappaB partially blocked HDGF knockdown-induced apoptosis and growth suppression.
- Simultaneous inactivation of both intrinsic and extrinsic pathways led to stronger inhibition.
Conclusions:
- HDGF functions as a survival factor through both intrinsic (Bad-mediated) and extrinsic (Fas-mediated) apoptotic pathways.
- HDGF is a potential therapeutic target for hepatocellular carcinoma and other cancers.
- The interplay between these pathways offers a more effective strategy for cancer therapy.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
07:25Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery
Published on: August 18, 2023